# TARPSWG VIRTUAL TUMOR BOARD CASE PRESENTATION

ALBERTO TAVARES DE LA PAZ CLAUDIA HAYDEE SARAÍ CANO

SURGICAL ONCOLOGY / PATHOLOGY LEON, GUANAJUATO, MEXICO



#### CASE PRESENTATION



23 year old female

No previous familiar or personal medical history


No previous surgeries

Presents to outside hospital

2-month history of palpable abdominal lump, rapid growth

Painless, no other symptoms





#### CASE PRESENTATION

No preoperative biopsy

October 2023: Wide local resection of abdominal wall

Mesh reconstruction



Surgical pathology report

High-grade epithelioid sarcoma
All positive margins
Extensive necrosis
High Ki-67

December 2023: Referred to State Oncologic Center

Staging chest, abdomen and pelvis CT: NED

Abdominal wall MRI:

Negative for gross residual / recurrent disease

## PATHOLOGY REVIEW



| Marcador  | S.<br>Sinovial | S.<br>Ewing | BCOR      | CIC/DUX4 | RABDO      | DCPRA   | S.Epiteloide | CASO  |
|-----------|----------------|-------------|-----------|----------|------------|---------|--------------|-------|
| S100      |                | -           | 1.//      | -        |            | +       | -/+          |       |
| CD99      | ++             | ++          | +         | +        | +          | PARANUC | Variable     | +     |
| CDK4      |                | -           | -         | -        | Para lea   | -       | 1-           | -     |
| FLI-1     | -/+            | +++         | -         | -        |            | -/+     |              | +++   |
| ERG       | -/+            | +++         | -         | -        | +          | -       | 9 -          | +++   |
| MYOD1     |                | -           | -         | -        | +++        |         | (.=)         | -     |
| MIOGENINA | *              | -           | -         | 1=0      | +++        | -       | -            | 100   |
| TLE-1     | +++            | - 1         | -         | -/+      | -11        | -/+     | +/-          |       |
| SATB2     | -              | - 1         | +++       | -        | -1/ b      | 100     | -            | -     |
| WT1       | -              | -/+         | -         | +/-      | -          | CITOPL  | -            | +     |
| DESMINA   | -              | -           | -         | -        | +          | PARANUC | -            | -     |
| PanCK     | +              | -           | -         | -        | -v. epitel | +       | +            |       |
| Cd34      | -              | -           | -         | -        | -          | -       | +++          | -     |
| EMA       | +/-            | -           | -/+       | -        | V. epitel  | +       | +            | -     |
| CD56      | ++             | -           | V         | -/+      | +++        | +/-     | -            | -     |
| INI-1     | NO MUT         | NO<br>MUT   | NO<br>MUT | NO MUT   | NO MUT     | NO MUT  | 50% MUT      | NO MU |
| SALL4     | -              | -           | -         | -        | -          | -       | -            |       |
| SS18-SSX  | +++            |             | -         | -        | -          | -       | -            | (-    |
| AML       | -              | -           | -         | -/+      | +          | +       | -            | 12    |
| HMB45     | -              | -           | -         | -        | -          | -       | -            | 17-   |
| MELAN A   | •              | -           | -         | (-)      | -          | -       | -            | -     |
| STAT6     | *              | -           | -         | -        | -          | -       | -            | -     |
| TFE3      |                | -           | *         |          | -          | -       | -            | 1.0   |
| CC10      |                |             |           |          |            |         |              |       |
| DUX4      | 1=1            | -           | -         | ++       | -          |         | <b>*</b> :   | ++    |

CIC-DUX4 sarcoma, epithelioid and rabdoid cells, with extensive necrosis

#### MULTIDISCIPLINARY DISCUSSION

#### January 2024

- Adjuvant chemotherapy with doxorubicin/ifosfamide (3c)
- Mexican Sarcoma Group tumor board
   Ultra-rare sarcoma, limited experience
- Escalation to TARPSWG international tumor board
  - Margin revision vs active surveillance
  - Role for further chemo / radiotherapy

#### **SUMMARY OF**

#### RECOMMENDATIONS Radiotherapy

- No role for adjuvant RT
- Consider preop RT if re-resection

#### Chemotherapy

- Rapid resistance development
- Maximize local control
- ChT as bridge to surgery

Surgery

Margin revision / reresection

Delayed reconstruction to ensure -ve margins


Short-term surveillance CTs

Rule out metastasis


Treat local recurrence when/if presents

### **EVOLUTION**

- Completed adjuvant doxorrubicin/ifosfamide6 cycles
- 5 months post-opCT chest/abdomen/pelvis: NED
- Public institution with no MRI availability
   No private insurance
   Abdominal wall MRI scheduled in April 2024




# THANKYOU





sarcoma.mx@gmail.com



@sarcoma\_mx



Registro de participantes Grupo Mexicano de Sarcomas



